Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).

Department of Chemistry, Laboratory of Organic Chemistry, University of Athens, Panepistimiopolis, Athens 15771, Greece. vmagriot@chem.uoa.gr

Expert opinion on therapeutic patents 2013 Mar

filter terms:

Phospholipases A(2) have been implicated in various pathological conditions, such as rheumatoid arthritis, cardiovascular diseases, neurological disorders and cancer. The scientific community focuses on the search of potent and selective PLA(2) inhibitors of each PLA(2) class in order to identify novel medicinal agents. At present, only one lipoprotein-associated PLA(2) (LpPLA(2)) inhibitor has reached Phase III clinical trials for the treatment of atherosclerosis. This review article focuses on the role of the most important PLA(2)s in inflammatory diseases and other severe pathological conditions presented in patent literature from June 2009 to September 2012. Even though the role of each PLA(2) in different diseases or pathological conditions is not yet definitively identified, the progress in the quest for potent and selective PLA(2) inhibitors is exciting and the use of such inhibitors as medicinal agent looks now more promising than ever.

Citation

Victoria Magrioti, George Kokotos. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present). Expert opinion on therapeutic patents. 2013 Mar;23(3):333-44